SWT 06101Alternative Names: SWT-06101
Latest Information Update: 29 Mar 2016
At a glance
- Originator SWITCH Biotech (CEASED)
- Developer SWITCH Biotech
- Class Analgesics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Fibromyalgia